8372 (8372) Fair Value & Analysis

Healthcare · Market cap HK$112M

8 8372 8372 · HK

PriceHK$0.1390

Fair ValueHK$0.1500

Upside+7.9%

Quality61/100

Watch 8372 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.1100 – HK$0.2100

Fair value as of: Jul 3, 2026

From 26 valuation models · updated today

Share price −0.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.0960 – HK$0.1630 · fair‑value band HK$0.1100 – HK$0.2100 · the HK$0.1390 price screens below the HK$0.1500 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8372 (8372) currently trades at HK$0.1390, while our model-based Fair Value estimate is HK$0.1500 — implying the stock looks roughly 7.9% undervalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 8372 generated revenue of HK$101M at a net margin of 8.4%. Revenue declined 8.6% year over year. It earns a return on equity of 7.1%. The balance sheet holds a net cash position of HK$51.1M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$101M

Revenue growth (YoY) -8.6%

Net margin 8.4%

Return on equity 7.1%

Free cash flow HK$1.2M FY2025

P/E ratio 14.0

More key figures

Operating margin 7.8%

EPS (TTM) HK$0.0200

Dividend yield 2.3%

EPS growth (YoY) -27.5%

Net cash HK$51.1M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

8372 reported revenue of HK$101M in FY2026 versus HK$72.0M in FY2022, a compound +8.8%/yr. Reported net income was HK$8.4M in FY2026, compounding +20.1%/yr from FY2022.

Revenue +8.8%/yr

FY22 HK$72.0M

FY23 HK$76.7M

FY24 HK$81.9M

FY25 HK$94.4M

FY26 HK$101M

Net income +20.1%/yr

FY22 HK$4.0M

FY23 HK$7.6M

FY24 HK$7.9M

FY25 HK$9.5M

FY26 HK$8.4M

Is 8372 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$999.49	R$1,236	+24%
Cencora, Inc C1CO34	R$707.04	R$79.88	-89%
Cardinal Health, Inc CAH	$201.74	$92.07	-54%
Sigma Healthcare Limited SIGGF	$2.35	$0.6300	-73%
SIG SIG	A$2.92	A$1.20	-59%
Shanghai Pharmaceuticals Holding 601607	¥15.96	¥45.15	+183%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 8372 (8372) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$0.1500 versus a price of HK$0.1390 — about +8% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 8372?

Our model-based fair value for 8372 is HK$0.1500 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$0.1390.

What is the quality score of 8372?

8372 has a Quality Score of 61/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 8372 (8372)?

8372 reported trailing-twelve-month revenue of about HK$101M (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 8372?

The net profit margin of 8372 is about 8.4%, meaning it keeps roughly 8.4% of revenue as net income. Based on the latest reported figures.

Does 8372 pay a dividend?

8372 currently shows a dividend yield of about 2.27% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.